Patient Characteristics
| Variable . | No. . | Category . | No. (%) of Evaluable Patients . |
|---|---|---|---|
| Sex | 338 | Female | 140 (41.4) |
| Male | 198 (58.6) | ||
| Age | 338 | <10 yr | 261 (77.2) |
| ≥10 yr | 77 (22.8) | ||
| WBC at diagnosis | 338 | <50 × 109/L | 237 (70.1) |
| ≥50 × 109/L | 101 (29.9) | ||
| NCI risk assignment | 338 | Standard risk | 183 (54.1) |
| Poor risk | 155 (45.9) | ||
| Lymphadenopathy | 338 | No | 166 (49.1) |
| Yes | 172 (50.9) | ||
| Splenomegaly | 337 | No | 158 (46.9) |
| Yes | 179 (53.1) | ||
| Hepatomegaly | 337 | No | 159 (47.2) |
| Yes | 178 (52.8) | ||
| Mediastinal mass | 338 | No | 295 (87.3) |
| Yes | 43 (12.7) | ||
| Immunophenotype | 338 | B-lineage | 286 (84.6) |
| T-lineage | 52 (15.4) | ||
| Molecular genetics | 215 | PCR neg. | 191 (88.8) |
| MLL-AF-4+ [t(4; 11)] | 4 (1.9) | ||
| E2A-PBX-1+ [t(1; 19)] | 11 (5.1) | ||
| BCR-ABL+ [t(9; 22)] | 9 (4.2) | ||
| SCID mouse assay | 295 | No Leukemia | 232 (78.6) |
| Leukemia | 63 (21.4) | ||
| Treatment response | |||
| Day 7 BM status | 324 | M1 or M2 (RER) | 246 (75.9) |
| M3 (SER) | 78 (24.1) | ||
| Day 28 BM status | 336 | M1 (CR) | 329 (97.9) |
| M2 or M3 (no CR) | 7 (2.1) |
| Variable . | No. . | Category . | No. (%) of Evaluable Patients . |
|---|---|---|---|
| Sex | 338 | Female | 140 (41.4) |
| Male | 198 (58.6) | ||
| Age | 338 | <10 yr | 261 (77.2) |
| ≥10 yr | 77 (22.8) | ||
| WBC at diagnosis | 338 | <50 × 109/L | 237 (70.1) |
| ≥50 × 109/L | 101 (29.9) | ||
| NCI risk assignment | 338 | Standard risk | 183 (54.1) |
| Poor risk | 155 (45.9) | ||
| Lymphadenopathy | 338 | No | 166 (49.1) |
| Yes | 172 (50.9) | ||
| Splenomegaly | 337 | No | 158 (46.9) |
| Yes | 179 (53.1) | ||
| Hepatomegaly | 337 | No | 159 (47.2) |
| Yes | 178 (52.8) | ||
| Mediastinal mass | 338 | No | 295 (87.3) |
| Yes | 43 (12.7) | ||
| Immunophenotype | 338 | B-lineage | 286 (84.6) |
| T-lineage | 52 (15.4) | ||
| Molecular genetics | 215 | PCR neg. | 191 (88.8) |
| MLL-AF-4+ [t(4; 11)] | 4 (1.9) | ||
| E2A-PBX-1+ [t(1; 19)] | 11 (5.1) | ||
| BCR-ABL+ [t(9; 22)] | 9 (4.2) | ||
| SCID mouse assay | 295 | No Leukemia | 232 (78.6) |
| Leukemia | 63 (21.4) | ||
| Treatment response | |||
| Day 7 BM status | 324 | M1 or M2 (RER) | 246 (75.9) |
| M3 (SER) | 78 (24.1) | ||
| Day 28 BM status | 336 | M1 (CR) | 329 (97.9) |
| M2 or M3 (no CR) | 7 (2.1) |
Leukemic cells are examined for the presence of MLL-AF-4, E2A-PBX-1 and BCR-ABL by RT-PCR, as described in Materials and Methods.
Abbreviations: BM, bone marrow; WBC, white blood count; BM status: M1, <5% blasts; M2, 5-25% blasts; M3, >25% blasts.